AHA Coding Clinic® for HCPCS - 2021 Issue 3; For Your Information

Revocation of EUA for COVID-19 monoclonal antibody treatment

Revocation of emergency use authorization (EUA) for the COVID-19 monoclonal antibody therapy bamlanivimab and deletion of HCPCS codes M0239 and Q0239 effective July 2021 The Centers for Medicare & Medicaid Services (CMS) listed new HCPCS codes M0239 and Q0239 that were established effective November 9, 2020, for bamlanivimab to track and pay appropriately for monoclonal antibodies used to treat COVID-19. The codes were added to the January 2021 I/OCE with their effective dates set to the dates they were authorized by the FDA. Effective April 16, 2021, the U.S. Food and Drug Administration revoked the emergency use...

To read the full article, sign in and subscribe to the AHA Coding Clinic® for HCPCS.

Thank you for choosing Find-A-Code, please Sign In to remove ads.